Recombinant human CD112R, also known as PVRIG (Poliovirus receptor-related Immunoglobulin domain-containing protein), encompassing amino acids 41-172. This construct containsan C-terminal Human IgG1, Fc region followed by an Avi-Tag™. The recombinant protein was affinity purified. HiP™ indicates a high purity protein with ≥90% purity as measured by gel filtration.
●
Synonyms
Poliovirus Receptor-related Immunoglobulin Domain-containing Protein, Transmembrane Protein PVRIG
●
Product Data Gallery
4-20% SDS-PAGE Coomassie Staining
Anti-PVRIG:PVRIG Biotin Binding Assay. *Not all lots have been tested for enzyme activity
8 mM Phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol.
MW
42 kDa
Amino Acids
41-172
Aggregation
<10%
Genbank #
NM_024070
UniProt #
Q6DKI7
Tag(s)
C-terminal Fc-Fusion- Avi-Tag
Label
This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation confirmed to be ≥90%.
For more information on enzymatic biotinylation, please see our Tech Note.
Background
CD112R (Poliovirus receptor-related immunoglobulin domain containing, PVRIG) is the receptor for CD112 (Poliovirus receptor-related 2, PVRL2) found on antigen-presenting cells and tumor cells. CD112R is present in NK and T cells, particularly CD8+ T cells. Elevated levels of this receptor are observed in NK, CD8+, and CD4+ T cells in patients with cancer of the kidney, ovary, lung, prostate, and endometrium, and in acute myeloid leukemia (AML). CD112-CD112R complex acts as a positive immune checkpoint, boosting human T cell response and serving as a promising therapeutic target in oncology. TIGIT (T cell immunoreceptor with Ig and ITIM domains) and CD226 (also known as DNAM-1, DNAX Accessory Molecule-1) also bind CD112. Developing inhibitors to hinder CD112R-CD112 interaction alone or combined with blocking TIGIT-CD155/CD112 interaction holds promise for cancer therapy.
References
1. Bottino, C., et al., J. Exp. Med. 2003; 198(4): 557-567.
2. Pende, D., et al., Blood. 2005; 105(5): 2066-2073
Storage/Stability
At least 6 months at -80°C.
Assay Conditions
The antibody was validated by measuring anti-PVRIG binding to PVRIG antigen in an ELISA assay. The anti-PVRIG protein (BPS Bioscience #101712) was coated onto a 96-well plate overnight at 4°C (50 µl/well at a concentration of 2 µg/ml in PBS). The plate was washed 3 times with Immuno Buffer 1 (BPS Bioscience #79311) and blocked using 100 µl of Blocking Buffer 2 (BPS Bioscience #79728) for 1 hour at room temperature. After removing the blocking buffer, 50 µl/well of serially diluted CD112R (PVRIG) Fc-Fusion, Avi-Tag, Biotin-Labeled (Human) (BPS Bioscience #79270), in Blocking Buffer 2 was added for 1 hour at room temperature. After 3 more washes, the plate was incubated with Streptavidin-HRP (BPS Bioscience #79742), washed, and incubated with the Colorimetric HRP substrate. The reaction was stopped, and absorbance was read at 450 nm. The Blank value was subtracted from all values.
Instructions for Use
Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Applications
Useful for binding of PVRIG in ELISA and in cellular assays.